Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes
Figure 8
Fc-FGF21(RG) had a prolonged efficacy in db/db or ob/ob mice.
(A-B) 8-9 week old male db/db mice were ip administered with FGF21 (A) or Fc-FGF21 (B) at various molar equivalent doses. The molar equal dose is defined as an equivalent molar dose of FGF21 as a unit. Blood glucose levels were measure at the indicated time points. (C–D) Effect of vehicle (closed circle), FGF21 (opened circle), Fc-FGF21(closed square) or Fc-FGF21(RG) (opened squared) on blood glucose levels (C) and body weight gains (D) following a single injection at a molar equivalent dose in db/db mice. Blood glucose levels and body weight were measured over a course of 144 h. (E–F) Dose-response and time course effects of Fc-FGF21(RG) on blood glucose levels (E) and body weight gains (F) in ob/ob mice. 8–9 week old male ob/ob mice were ip administered with various doses of Fc-FGF21(RG). Blood glucose levels and body weight were measured over a course of 168 h. All data are mean ± SEM, n = 9–10 animals per group, * p<0.05, ̂ p<0.01, # p<0.001 compared with vehicle at each time point.